The announcement regarding the vaccine of Janssen/Johnson & Johnson It appeared to be a moderately effective vaccine, but in essence, With just one dose, the vaccine provides 85% protection against the serious effects of the disease. Even more importantly, 49 days after vaccination, there were no reported hospitalizations or deaths, he emphasizes in a post on Facebook, the professor of Health Policy, Elias Mosialos of London School of Economics and Political Science (LSE).
As he points out, according to the company's announcement, this applies to all countries where clinical trials were conducted. Even in the South Africa (Editor's note: where the new, more contagious strain of the virus appeared) coronavirus (which was recently detected in Greece as well), where the vaccine was not highly effective and some people contracted the virus despite being vaccinated, did not develop serious symptoms. This vaccine is the only one we have so far—and it will soon submit an application for emergency use authorization— that requires only one dose, while the Phase III clinical trial is still ongoing, in which volunteers receive two doses of the vaccine.
Mr. Mosialos presents a table containing a simple comparative analysis of the seven vaccines and some data on the effectiveness of the dominant strain and the two major variants. «What’s most important right now,» he says, «is to increase vaccine production and distribution, as well as the pace of vaccinations. »That's the only way the pandemic will end.".
It also notes that, just as vaccines differ in their design, so too were their clinical trials for COVID-19 designed with variations: in the number of volunteers, the method and frequency of data collection, the interim analysis points for symptomatic participants, and many other aspects. However, by simply compiling the key data on the leading vaccines currently being administered worldwide, we see that Some of the approved vaccines—for which we have the relevant publications and clinical data—appear to have exceptional efficacy data, such as those from Pfizer-BioNTech and Moderna.
In the case of Pfizer, there is also confirmation through vaccinations in the Israel. «Some other vaccines,» as he points out, «are lagging behind in terms of publishing results from large clinical trials, such as the Russian one Sputnik-V, but »It has an excellent design, and based on the announcements, it also appears to be highly effective.".
It also notes that the obstacle course of mass vaccinations had to grapple with the issue of production and distribution from the very beginning. Now, with new variants already surging in some countries and spreading to others, some companies have begun planning to adapt their vaccines, Some are already testing them in clinical trials (e.g.,. AstraZeneca) and for some we already have some results (e.g.,. Novavax and Janssen/Johnson & Johnson).
The Belgian pharmaceutical company Janssen is part of the group of companies owned by the American multinational Johnson & Johnson.
A comparative table of vaccines is attached
